TABLE 1.

Patient and Diagnostic Characteristics

CharacteristicAll patients (n = 154)pN0 patients (n = 99)pN1 patients (n = 55)P
Age (y)68 (63–72)68 (63–72)69 (63–73)0.52
Initial PSA (μg/L)12 (7–21)11 (6–19)14 (8–34)0.03
Clinical tumor stage0.01
 cT1c19 (12)14 (14)5 (9)
 cT283 (54)60 (61)23 (42)
 cT346 (30)23 (23)23 (42)
 cT45 (3)1 (1)4 (7)
 cTx1 (1)1 (1)0 (0)
Radiologic tumor stage*<0.001
 mT257 (37)48 (49)9 (16)
 mT390 (58)49 (50)41 (75)
 mT47 (5)2 (2)5 (9)
ISUP grade group0.007
 11 (1)1 (1)0 (0)
 222 (14)13 (13)9 (16)
 356 (36)43 (43)13 (24)
 437 (24)26 (26)11 (20)
 538 (25)16 (16)22(40)
EAU risk group0.003
 Intermediate30 (19)25 (25)5 (9)
 High73 (47)50 (51)23 (42)
 Locally advanced51 (33)24 (24)27 (49)
Briganti risk of LN metastasis29 (15–52)21 (13–41)47 (28–75)<0.001
PSMA tracer0.75
 68Ga-PSMA-1165 (42)44 (44)21 (38)
 18F-DCFPyl48 (31)31 (31)17 (31)
 18F-PSMA-100730 (19)19 (19)11 (20)
 18F-JK-PSMA-711 (7)5 (5)6 (11)
Interval, PSMA to SN (d)63 (43–78)63 (44–84)64 (42–78)0.86
SPECT/CT-identified SNs3 (2–4)3 (2–4)3 (2–4)0.50
SNs removed3 (2–4)2 (2–4)3 (2–4)0.15
SNs positive1 (1–2)
Metastasis size (mm)3 (1–4)
Distribution SN/non-SN
 Positive SNs only50 (91)
 Positive SNs + non-SNs1 (2)
 Positive non-SNs only4 (7)
  • * Based on MRI.

  • PSA = prostate-specific antigen; ISUP = International Society of Uropathology; EAU = European Association of Urology.

  • Qualitative data are number and percentage; continuous data are median and interquartile range.